Highly Active Antiretroviral Treatment (HAART) of Human Immunodeficiency Virus (HIV)-infection in a town in Cameroon: randomised controlled study to suggest which treatment starting point is most beneficial for the patients
Not Applicable
Completed
- Conditions
- HIVInfections and InfestationsHIV infection
- Registration Number
- ISRCTN22114173
- Lead Sponsor
- Institute of Community Medicine, University of Tromsø (Norway)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
1. Treatment naive Human Immunodeficiency Virus (HIV)-infected individuals
2. 16 years of age or older
3. CD4 count between 450 and 250 cells/mm^3
Exclusion Criteria
1. If patient fulfils current indications for immediate treatment: CD4 less than 250 cells/mm^3 or WHO clinical stage 3 or 4
2. If CD4 is currently greater than 450 cells/mm^3 . This is because patient will probably not start Anti-Retroviral Therapy (ART) during the first year to come
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. WHO clinical stage, assessed after one and possibly also after two years of treatment<br>2. Changes in CD4 count after randomisation and after start of treatment
- Secondary Outcome Measures
Name Time Method 1. Weight maintenanace<br>2. Intercurrent diseases<br>3. Acquired Immune Deficiency Syndrome (AIDS) development<br>4. Survival